A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC (ARMOR3-SV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02438007

Recruitment Status : Terminated

First Posted : May 8, 2015

Last Update Posted : September 28, 2017

Sponsor:

Information provided by (Responsible Party):

Novus Therapeutics, Inc

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Terminated
Actual Primary Completion Date :	July 2016
Actual Study Completion Date :	November 2016
Certification/Extension First Submitted :	September 21, 2017

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Aragon-Ching JB. The promising role of poly(ADP-ribose) polymerase inhibitors in prostate cancer. Asian J Androl. 2016 Jul-Aug;18(4):592-3. doi: 10.4103/1008-682X.172821.

To Top